Latest Healthcare News

Artrya Limited reported a 17.2% increase in net loss to $16.4 million for FY25, while achieving FDA clearance and launching its AI-driven Salix platform in the U.S. market. The company also secured key commercial partnerships in Australia and raised $20 million in equity funding.

Prescient Therapeutics reported an 11.1% reduction in net loss for FY2025, progressing its lead candidate PTX-100 into Phase 2a trials with FDA Fast Track and Orphan Drug designations, supported by a recent $9.8 million capital raise.

Universal Biosensors Pty Limited has entered voluntary administration with KPMG appointed as administrators, signaling urgent financial distress and a potential restructuring ahead.

Genetic Technologies Limited has emerged from voluntary administration following a strategic asset sale and is now pursuing recapitalisation and acquisitions to restore its market position.

Genetic Technologies Limited reports a 36% increase in half-year losses amid voluntary administration, followed by a recapitalisation and sale of core assets. The company pivots towards new financial services acquisitions under fresh leadership.

Invion Limited secures a pivotal FDA Orphan Drug Designation for its lead candidate INV043, targeting anal cancer with promising preclinical results and a fast-tracked development path.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Monash IVF Group has completed an independent review into two separate clinic incidents involving non-standard IVF treatments, revealing human errors and IT system issues. The company commits to enhanced safeguards without expecting significant financial impact.

LTR Pharma’s intranasal ED treatment SPONTAN achieves peak effect up to five times faster than oral tablets, according to new peer-reviewed clinical data published in a leading European journal.

Pharmx Technologies reported a 13% increase in FY25 revenues to $7.53 million, driven by strong growth across its Gateway and Marketplace platforms. The company maintained positive EBITDA and a solid cash position despite legal expenses, setting the stage for an ambitious FY26 growth strategy.

Pharmx Technologies has reported a 13% revenue increase to $7.5 million for FY25, driven by expanded partnerships and platform innovations, despite a dip in EBITDA due to heavy investment.

Opthea Limited has terminated its sozinibercept wet AMD program following Phase 3 trial failures and settled a major funding agreement, setting the stage for a strategic reset.